New targeted therapy tested for tough blood cancers

NCT ID NCT06179511

Summary

This early-stage study is testing a new drug called AZD9829 for people with certain hard-to-treat blood cancers that have a marker called CD123. The main goals are to find a safe dose and see if the drug shows early signs of fighting the cancer. It is for adults whose cancer has come back or hasn't responded to previous treatments.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOLOGICAL MALIGNANCIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Research Site

    Duarte, California, 91010, United States

  • Research Site

    St Louis, Missouri, 63110, United States

  • Research Site

    New York, New York, 10021, United States

  • Research Site

    Chapel Hill, North Carolina, 27514, United States

  • Research Site

    Columbus, Ohio, 43210, United States

  • Research Site

    Houston, Texas, 77030, United States

  • Research Site

    Milwaukee, Wisconsin, 53226, United States

  • Research Site

    Heidelberg, 3084, Australia

  • Research Site

    Melbourne, VIC 3000, Australia

  • Research Site

    Tianjin, 300020, China

  • Research Site

    Frankfurt, 60590, Germany

  • Research Site

    Bologna, 40138, Italy

  • Research Site

    Kashiwa, 227-8577, Japan

  • Research Site

    Osaka, 545-8586, Japan

  • Research Site

    Yoshida-gun, 910-1193, Japan

  • Research Site

    Seoul, 03080, South Korea

  • Research Site

    Seoul, 05505, South Korea

  • Research Site

    Barcelona, 08035, Spain

  • Research Site

    Salamanca, 37007, Spain

  • Research Site

    Tainan, 704, Taiwan

  • Research Site

    Taipei, 10002, Taiwan

  • Research Site

    Manchester, M204BX, United Kingdom

Conditions

Explore the condition pages connected to this study.